116 related articles for article (PubMed ID: 32473599)
1. A real-time cell-binding assay reveals dynamic features of STxB-Gb3 cointernalization and STxB-mediated cargo delivery into cancer cells.
Encarnação JC; Napolitano V; Opassi G; Danielson UH; Dubin G; Popowicz GM; Munier-Lehmann H; Buijs J; Andersson K; Björkelund H
FEBS Lett; 2020 Aug; 594(15):2406-2420. PubMed ID: 32473599
[TBL] [Abstract][Full Text] [Related]
2. Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit.
Geyer PE; Maak M; Nitsche U; Perl M; Novotny A; Slotta-Huspenina J; Dransart E; Holtorf A; Johannes L; Janssen KP
Mol Cancer Ther; 2016 May; 15(5):1008-17. PubMed ID: 26826119
[TBL] [Abstract][Full Text] [Related]
3. Potent in vitro antitumor activity of B-subunit of Shiga toxin conjugated to the diphtheria toxin against breast cancer.
Mohseni Z; Sedighian H; Halabian R; Amani J; Behzadi E; Imani Fooladi AA
Eur J Pharmacol; 2021 May; 899():174057. PubMed ID: 33753109
[TBL] [Abstract][Full Text] [Related]
4. Intracellular drug delivery: Potential usefulness of engineered Shiga toxin subunit B for targeted cancer therapy.
Luginbuehl V; Meier N; Kovar K; Rohrer J
Biotechnol Adv; 2018; 36(3):613-623. PubMed ID: 29432805
[TBL] [Abstract][Full Text] [Related]
5. Membrane invagination induced by Shiga toxin B-subunit: from molecular structure to tube formation.
Pezeshkian W; Hansen AG; Johannes L; Khandelia H; Shillcock JC; Kumar PB; Ipsen JH
Soft Matter; 2016 Jun; 12(23):5164-71. PubMed ID: 27070906
[TBL] [Abstract][Full Text] [Related]
6. Trafficking of Shiga toxin/Shiga-like toxin-1 in human glomerular microvascular endothelial cells and human mesangial cells.
Warnier M; Römer W; Geelen J; Lesieur J; Amessou M; van den Heuvel L; Monnens L; Johannes L
Kidney Int; 2006 Dec; 70(12):2085-91. PubMed ID: 17063173
[TBL] [Abstract][Full Text] [Related]
7. Tumor delivery of ultrasound contrast agents using Shiga toxin B subunit.
Couture O; Dransart E; Dehay S; Nemati F; Decaudin D; Johannes L; Tanter M
Mol Imaging; 2011 Apr; 10(2):135-43. PubMed ID: 21439258
[TBL] [Abstract][Full Text] [Related]
8. Differential recognition of lipid domains by two Gb3-binding lectins.
Schubert T; Sych T; Madl J; Xu M; Omidvar R; Patalag LJ; Ries A; Kettelhoit K; Brandel A; Mely Y; Steinem C; Werz DB; Thuenauer R; Römer W
Sci Rep; 2020 Jun; 10(1):9752. PubMed ID: 32546842
[TBL] [Abstract][Full Text] [Related]
9. Repurposing the Pentameric B-Subunit of Shiga Toxin for Gb3-Targeted Immunotherapy of Colorectal Cancer by Rhamnose Conjugation.
Liu Z; Li X; Lu Z; Qin X; Hong H; Zhou Z; Pieters RJ; Shi J; Wu Z
J Pharm Sci; 2022 Oct; 111(10):2719-2729. PubMed ID: 35905973
[TBL] [Abstract][Full Text] [Related]
10. Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds.
Stimmer L; Dehay S; Nemati F; Massonnet G; Richon S; Decaudin D; Klijanienko J; Johannes L
BMC Cancer; 2014 Dec; 14():916. PubMed ID: 25476116
[TBL] [Abstract][Full Text] [Related]
11. Gb3-binding lectins as potential carriers for transcellular drug delivery.
Müller SK; Wilhelm I; Schubert T; Zittlau K; Imberty A; Madl J; Eierhoff T; Thuenauer R; Römer W
Expert Opin Drug Deliv; 2017 Feb; 14(2):141-153. PubMed ID: 27935765
[TBL] [Abstract][Full Text] [Related]
12. Intracellular trafficking of Shiga-toxin-B-subunit-functionalized spherulites.
Bouter A; Delord B; Dransart E; Poirier C; Johannes L; van Effenterre D
Biol Cell; 2008 Dec; 100(12):717-25. PubMed ID: 18564063
[TBL] [Abstract][Full Text] [Related]
13. Shiga toxin and its use in targeted cancer therapy and imaging.
Engedal N; Skotland T; Torgersen ML; Sandvig K
Microb Biotechnol; 2011 Jan; 4(1):32-46. PubMed ID: 21255370
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific targeting of pancreatic cancer with Shiga toxin B-subunit.
Maak M; Nitsche U; Keller L; Wolf P; Sarr M; Thiebaud M; Rosenberg R; Langer R; Kleeff J; Friess H; Johannes L; Janssen KP
Mol Cancer Ther; 2011 Oct; 10(10):1918-28. PubMed ID: 21788400
[TBL] [Abstract][Full Text] [Related]
15. In vivo tumor targeting by the B-subunit of shiga toxin.
Viel T; Dransart E; Nemati F; Henry E; Thézé B; Decaudin D; Lewandowski D; Boisgard R; Johannes L; Tavitian B
Mol Imaging; 2008; 7(6):239-47. PubMed ID: 19123994
[TBL] [Abstract][Full Text] [Related]
16. Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool.
Falguières T; Maak M; von Weyhern C; Sarr M; Sastre X; Poupon MF; Robine S; Johannes L; Janssen KP
Mol Cancer Ther; 2008 Aug; 7(8):2498-508. PubMed ID: 18687997
[TBL] [Abstract][Full Text] [Related]
17. Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma.
Ehrenfeld M; Schrade A; Flisikowska T; Perl M; Hirsch ND; Sichler A; Geyer L; Flisikowski K; Wilhelm D; Schober SJ; Johannes L; Schnieke A; Janssen KP
Mol Cancer Ther; 2022 Apr; 21(4):686-699. PubMed ID: 35086950
[TBL] [Abstract][Full Text] [Related]
18. 2-Hydroxy Fatty Acid Enantiomers of Gb3 Impact Shiga Toxin Binding and Membrane Organization.
Schütte OM; Patalag LJ; Weber LM; Ries A; Römer W; Werz DB; Steinem C
Biophys J; 2015 Jun; 108(12):2775-8. PubMed ID: 26083916
[TBL] [Abstract][Full Text] [Related]
19. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity.
Vingert B; Adotevi O; Patin D; Jung S; Shrikant P; Freyburger L; Eppolito C; Sapoznikov A; Amessou M; Quintin-Colonna F; Fridman WH; Johannes L; Tartour E
Eur J Immunol; 2006 May; 36(5):1124-35. PubMed ID: 16568496
[TBL] [Abstract][Full Text] [Related]
20. Key role of receptor density in colloid/cell specific interaction: a quantitative biomimetic study on giant vesicles.
Lamblet M; Delord B; Johannes L; van Effenterre D; Bassereau P
Eur Phys J E Soft Matter; 2008; 26(1-2):205-16. PubMed ID: 18480963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
